Breast Cancer
📧 Sign up to get email alerts when something new happens for Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-03-14Clinical Trial Update: Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer [Phase 2]
Phase 2 trial evaluating whether adding trastuzumab to chemotherapy improves outcomes in stage II or III breast cancer; results posted 2023-…
-
CLINICAL_TRIALS trial_result · 2023-03-14Clinical Trial Update: Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer [Phase 2]
Phase 2 clinical trial of tamoxifen citrate in metastatic or recurrent breast cancer completed; results posted.
-
CLINICAL_TRIALS trial_result · 2023-03-13Clinical Trial Update: Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant [Phase 2]
A Phase 2 trial evaluating palbociclib in combination with an aromatase inhibitor or fulvestrant in women with advanced breast cancer has co…
-
CLINICAL_TRIALS trial_result · 2023-03-13Clinical Trial Update: Effectiveness of Combined Erector Spinae and Pecto-intercostal Fascial Plane Blocks Versus Thoracic Paravertebral Block in Perioperative Pain in Modified Radical Mastectomy [Phase 4]
Phase 4 trial evaluating the effectiveness of combined erector spinae and pecto-intercostal fascial plane blocks versus thoracic paravertebr…
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) [Phase 2]
This clinical trial update reports on a Phase 2 study comparing giredestrant with physician's choice of endocrine therapy in previously trea…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant [Phase 3]
Phase 3 trial comparing fulvestrant alone versus fulvestrant plus palbociclib in operable breast cancer responding to fulvestrant has comple…
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial exploring pre-surgical treatment with carboplatin and an albumin-stabilized nanoparticle formulation of paclitaxel in patien…
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer [Phase 3]
Phase 3 trial evaluating neoadjuvant hormonal therapy plus palbociclib in operable, hormone receptor–positive, HER2-negative breast cancer h…
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer [Phase 1]
Phase 1 clinical trial update for giredestrant (GDC-9545) in postmenopausal women with operable stage I-III estrogen receptor-positive breas…
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Optimization of Remotely Delivered Physical Activity Intervention for Breast Cancer Survivors [NA]
A completed clinical trial evaluating a remotely delivered physical activity intervention for breast cancer survivors; results posted in 202…
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer [Phase 2]
Phase 2 trial update evaluating Cu64-DOTA-trastuzumab PET imaging and biomarkers to predict response to neoadjuvant trastuzumab plus pertuzu…
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: Efficacy of Metformin as Preventive Treatment in Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients [Phase 2]
A Phase 2 trial investigated metformin as preventive treatment for paclitaxel-induced peripheral neuropathy in breast cancer patients; the s…
-
CLINICAL_TRIALS trial_result · 2023-03-08Clinical Trial Update: Immunological Variables Associated to ICI Toxicity in Cancer Patients [Phase 2]
A Phase 2 clinical trial investigating immunological variables associated with immune checkpoint inhibitor toxicity in cancer patients.
-
CLINICAL_TRIALS trial_result · 2023-03-07Clinical Trial Update: Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer [Phase 1, Phase 2]
Phase 1/2 trial update evaluating pyrotinib, dalpiciclib (SHR6390), and endocrine therapy in ER+/HER2+ advanced breast cancer. Status unknow…
-
FDA approval · 2023-03-07FDA Approved: GEMCITABINE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s generic gemcitabine under an Original Application (ANDA). This marks the approval of a generic…
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients [Phase 1, Phase 2]
Phase 1/2 trial evaluating neoadjuvant chemotherapy with Myocet, Taxotere, and Herceptin for HER2-positive breast cancer has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer [Phase 3]
Phase 3 trial update evaluating fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel in early breast cancer.
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients [Phase 2]
Phase 2 trial comparing exemestane to anastrozole as first-line hormone therapy in postmenopausal metastatic breast cancer.
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients [Phase 2]
Phase 2 trial evaluating neoadjuvant Gemcitabine, Doxorubicin, and Paclitaxel (GAT) in breast cancer patients has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling [Phase 2]
Phase 2 trial investigating neoadjuvant chemotherapy with trastuzumab and pertuzumab in HER2-negative breast cancer patients with abnormal H…
-
FDA approval · 2023-03-03FDA Approved: VERZENIO — Supplemental Application (Eli Lilly and Company)
FDA approves a supplemental application for VERZENIO (abemaciclib) submitted by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2023-03-03Clinical Trial Update: A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound) [Phase 3]
A Phase 3 trial evaluating SYHX2011 versus paclitaxel for advanced breast cancer is ongoing, with no current status reported.
-
CLINICAL_TRIALS trial_result · 2023-03-02Clinical Trial Update: TAC Versus TC for Adjuvant Breast Cancer [Phase 3]
A Phase 3 trial comparing TAC versus TC for adjuvant breast cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-03-01Clinical Trial Update: Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer [Phase 2]
Phase 2 trial update for neoadjuvant Inetetamab with pertuzumab and paclitaxel/carboplatin in locally advanced breast cancer is reported, wi…
-
CLINICAL_TRIALS trial_result · 2023-03-01Clinical Trial Update: Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer. [Phase 2]
A Phase 2 clinical trial update on neoadjuvant treatment for low HR expression, HER2-negative early breast cancer combining chidamide, PD-1 …